Jasper Therapeutics, Inc.   Report issue

For profit Phase 2
Founded: Redwood City CA United States (2018)

Organization Overview

First Clinical Trial
2020
NCT04429191
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Jasper Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

jsp191 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Myelodysplastic Syndromes (Phase 1)

Preleukemia (Phase 1)

Syndrome (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1